PatientsVille.com Logo

ALANINE AMINOTRANSFERASE INCREASED and Methadone

PatientsVille

ALANINE AMINOTRANSFERASE INCREASED Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for ALANINE AMINOTRANSFERASE INCREASED

ALANINE AMINOTRANSFERASE INCREASED treatment research studies

Methadone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Methadone Side Effects

Toxicity To Various Agents (601)
Cardiac Arrest (334)
Respiratory Arrest (316)
Completed Suicide (256)
Overdose (197)
Death (147)
Electrocardiogram Qt Prolonged (142)
Torsade De Pointes (97)
Respiratory Depression (82)
Cardio-respiratory Arrest (73)
Somnolence (65)
Accidental Overdose (59)
Nausea (57)
Pulmonary Oedema (57)
Loss Of Consciousness (54)
Vomiting (51)
Confusional State (47)
Pneumonia (40)
Dyspnoea (39)
Syncope (39)
Mental Status Changes (38)
Pain (37)
Fall (37)
Sedation (36)
Bronchopneumonia (36)
Dizziness (35)
Hypotension (31)
Convulsion (31)
Hyperhidrosis (31)
Malaise (30)
Depressed Level Of Consciousness (30)
Coma (29)
Unresponsive To Stimuli (27)
Intentional Overdose (27)
Constipation (27)
Feeling Abnormal (26)
Hypokalaemia (26)
Pulmonary Congestion (26)
Renal Failure Acute (26)
Ventricular Tachycardia (25)
Headache (25)
Fatigue (25)
Brain Oedema (25)
Lethargy (24)
Rhabdomyolysis (24)
Respiratory Failure (24)
Incorrect Dose Administered (23)
Bradycardia (23)
Accidental Poisoning (23)
Miosis (22)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<span style='color: #808080;'>My ALT is 66. What does that mean?

Good afternoon doc,my name dimasautisme,i comefrom indonesia ? im methadoners with 120 mg,im drink ARV to?please private my status? i just want quesstion i want to detox,where i must go to hospital doc? please help me :-D :)

I have been on methadone for two years. Went fro 70 mgs a day to 20. I do for pain and I have been prescribed klonipin also recently for severe panic attacks and I read online that it's a deadly combo. I take my methadone at 9 am. And have panic

I just got my report. the expected level for ALT is in between 0 + 40. where my alt is 60

Itching

Ive been takeing 90mls of methadone for approxamitley 2 years on and off but properly this time for a total off 7 months i get servere sweating from taking my methadone and feel very hot like im burning up and dripping with sweat why is this happenin

Methodone Side Effects, I have had many trips to Emergency Unit at my Town, having tight painful heart problems. But when they do the Tests for Heart attacks, I jave always been told I have no problem my heart is fine. I have had ECG Tests, all fine.

My alt level haso gone up to 60 (ref level 0 - 40). currently i'm using orciprenaline. is that the reason for this increase?

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

after taking my medicine .i felt abnormal taste in mouth and my bilurubin level was increased.

Unresponsive to 5mg/kg q 8wks; increased to 10mg/kg q6wks. After 3 doses at that strength noted fatigue, occasional night sweats, joint aches, sudden onset of chest pain and dyspnea (pleurisy, small pleuraleffusion) Had just taper

<span style='color: #808080;'>Took Diprophos for rheumatoid arthritis. Side effects: insomnia for 2 nights, perspiring during night, redness in face. Increased need to urinate.

Since starting champix i have experienced severral side effects including: -increased urination -lower back pain -extreme fatigue -mood swings -decrease in sex drive

<strong>I took 2 capsules at 7.20m after having breakfast and started feeling side effects at 8.25am. It started with increased temperature, abnormal levels of perspiration, dizziness and severe nausea. </strong

1+ years on this carvedilol 12.5 once a day then increased to 2x per day. Asthma symptoms, tightness in the chest, confusion, dizziness, some heart palpitation, ringing in the ears, disorientation (the worst). 57 yr old male, reasonable health for a

10 years on effexor, weight gain of 20 lbs last 5 years when increased to 300mg., no change in cal or exercise, since getting older realized needed fewre calories so tried to reduce like always could wirhWW and exercise, no success, couldn'

ALANINE AMINOTRANSFERASE INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting The Use of Methadone in Newborn Infants
Conditions: Premature Birth of Newborn;   Critically Ill
Intervention: Drug: Methadone
Outcome Measures: Methadone PK and EDDP;   DNA
2 Recruiting Methadone in Pediatric Anesthesiology II
Condition: Pain
Interventions: Drug: Group 1- 0.4mg/kg IV Methadone HCl;   Drug: Group 2 - 0.5mg/kg IV methadon HCI;   Other: Group 3 - control no Methadone
Outcome Measures: Morphine consumption;   Pain scores;   Methadone clearance
3 Recruiting CYP2B6 Polymorphisms in Methadone
Condition: Healthy Volunteers
Interventions: Drug: racemic Methadone HC1;   Drug: Oral deuterated racemic Methadone HCl,
Outcome Measures: The effects of Methadone on healthy volunteers;   Methadone and bupropion concentration;   Methadone and bupropion clearance from the body;   Oral Methadone and bupropion absorption;   Influence of CYP2B6*6 hetero or homozyge genotype on the above primary and secondary outcomes
4 Unknown  Compare Methadone Combined With N-Acetyl-Cysteine (NAC) and Methadone Alone for Opioids Astaining
Condition: Opioids Use
Interventions: Drug: Methadone; NAC;   Drug: Methadone
Outcome Measure:
5 Recruiting Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
Conditions: Pain;   Cancer of Head and Neck
Interventions: Drug: fentanyl;   Drug: Methadone
Outcome Measures: significant pain relief (reduction of Numeric Rating Scale (NRS) of 50%);   time to achieve significant pain relief;   side-effect profile
6 Recruiting Methadone vs Magnesium in Spinal Fusion
Condition: Idiopathic Scoliosis
Interventions: Drug: Methadone hydrochloride;   Drug: Magnesium Sulfate;   Drug: Remifentanil
Outcome Measures: Intra- and Post-operative Pain Relief;   Intra-operative parameters
7 Not yet recruiting Drug Interaction & Methadone & Buprenorphine
Condition: Hepatitis C
Interventions: Drug: Methadone;   Drug: DCV 3DAA FDC;   Drug: BMS-791325;   Drug: Buprenorphine;   Drug: Naloxone
Outcome Measures: Maximum observed concentration (Cmax) of R-Methadone for Part 1;   Area under the concentration-time curve in one dosing interval (AUC(TAU)) of R-Methadone for Part 1;   Cmax of Buprenorphine and Norbuprenorphine for Part 2;   AUC(TAU) of Buprenorphine and Norbuprenorphine for Part 2;   Cmax of S-Methadone and Total Methadone for Part 1;   AUC(TAU) of S-Methadone and Total Methadone for Part 1;   Concentration at 24 hours (C24) of S-Methadone, Total Methadone and R-Methadone for Part 1;   Time of maximum observed concentration (Tmax) of S-Methadone, Total Methadone and R-Methadone for Part 1;   C24 of Buprenorphine and Norbuprenorphine for Part 2;   Tmax of Buprenorphine and Norbuprenorphine for Part 2;   Ratio of metabolite AUC(TAU) to parent AUC(TAU) (MR_AUC(TAU)) of Norbuprenorphine to Buprenorphine;   Cmax of of Daclatasvir (DCV) , Asunaprevir (ASV) , BMS-791325, and BMS-794712;   AUC(TAU) of DCV, ASV, BMS-791325, and BMS-794712;   Concentration at 12 hours (C12) of DCV, ASV, BMS-791325, and BMS-794712;   Tmax of DCV, ASV, BMS-791325, and BMS-794712;   MR_AUC(TAU) for BMS-794712 to BMS-791325;   Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), death and AEs leading to discontinuation;   Results of vital signs, Electrocardiograms (ECGs), Physical Examinations (PEs) and clinical labs;   Scores of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), and Opiate Overdose Assessment (OOA)
8 Recruiting Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal
Condition: Opiate Withdrawal Syndrome
Intervention: Drug: Methadone
Outcome Measures: PK Parameters after multiple doses of enteral Methadone;   PK of Methadone's primary metabolite EDDP;   PK of R- and S-enantiomers of Methadone;   Correlation between plasma and DBS samples;   Correlation between plasma and scavenge samples;   Influence of CYP3A4 and CYP3B6 genetic polymorphisms on Methadone PK;   Methadone pharmacodynamics using the WAT-1;   Adverse events
9 Unknown  Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone
Conditions: Post Operative Pain;   Hyperalgesia
Interventions: Drug: ketamine infusion;   Drug: Methadone PCA
Outcome Measures: the extent of hyperalgesia area proximal to surgical wound;   pain intensity;   opioids related adverse events
10 Unknown  Methadone Versus Morphine for Orthopedic Surgery Patients
Conditions: Fracture;   Pain, Postoperative
Interventions: Drug: Methadone;   Drug: Morphine
Outcome Measures: Opioid consumption during the 48 hours after surgery;   Time to initial dose of rescue analgesic;   Overall rescue analgesic;   Side effects with special attention paid to respiratory rate and possible respiratory depression, and PONV;   Overall satisfaction of the patient with the analgesic graded on a scale of 1-5
11 Recruiting Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.
Condition: Pain Related to Cancer
Intervention: Drug: Methadone
Outcome Measure: Binary main criterion based on success/failure rate related to Methadone switch on Day 4.
12 Unknown  Efficacy of Drug and Risk Counseling Among Methadone Patients in Jakarta, Indonesia
Conditions: HIV Risk Behaviors;   Heroin Injection;   Retention in Methadone Treatment
Interventions: Behavioral: Behavioral Drug and Risk Counseling (BDRC);   Behavioral: Methadone maintenance treatment
Outcome Measures: Injection drug use;   retention in Methadone treatment
13 Unknown  Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone
Condition: Substance-Related Disorders
Interventions: Drug: midazolam(drug), digoxin (drug);   Drug: Bupropion (drug);   Drug: Methadone (drug)
Outcome Measures: Explore if there is a correlation between the areas of the concentration curves of probe substrates for CYP3A4 and/or CYP2B6 and Pgp and the area of the concentration curve of Methadone.;   LC-MS assays will be developed to analyze the plasma content of the probe substrates, Methadone and their metabolites. Specifically, midazolam, 1-OH midazolam, bupropion, t-butyl-hydroxy bupropion, digoxin, Methadone, and EDDP (a Methadone metabolite).;   Isolate and bank the DNA of the subjects for future genotyping of variant alleles that will be identified in this study to be important in Methadone pharmacokinetics.
14 Recruiting Efficacy Methadone for Management Postoperative Pain After the Use of Anesthesia Intravenous in Laparoscopic Cholecystectomy
Condition: Pain, Postoperative
Interventions: Drug: Morphine;   Drug: Methadone;   Drug: TIVA
Outcome Measures: Difference in milligrams of morphine used as rescue analgesia;   Difference in pain scores, using the Numeric Rating Scale
15 Not yet recruiting Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients
Conditions: Cigarette Smoking;   Methadone Maintenance
Interventions: Drug: Nicotine Nasal Spray;   Drug: Varenicline;   Drug: Placebo Nasal Spray;   Drug: Placebo Varenicline
Outcome Measures: Proportion of daily cigarettes smoked in the 4 hours after receiving Methadone dose;   Cigarettes per day;   Carbon monoxide level
16 Recruiting Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine
Conditions: Opiate Dependent;   Previous Illicit Drug Use
Intervention: Drug: Buprenorphine and Methadone Hydrochloride
Outcome Measures: Measurement of the pupil diameter;   - The mechanical punctuate pain threshold as measured by Electronical Von Frey;   - The mechanical pressure pain threshold measured by Algometer on the tibial bone;   - The pupil diameter measured in scotopic .conditions (via infrared camera) at the hypothetical peak effect of either Methadone or buprenorphine.;   - The pupil diameter measured in photopic conditions (via infrared camera) at the hypothetical residual effect of either Methadone or buprenorphine
17 Recruiting Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Condition: Low Back Pain
Interventions: Drug: Methadone;   Drug: Buprenorphine/naloxone
Outcome Measures: Analgesia;   Illicit drug use;   Cravings;   Functioning;   Depression;   Treatment retention
18 Recruiting Conversion From Parenteral to Oral Methadone.
Condition: Pain
Interventions: Drug: Parenteral /oral Methadone ratio 1:2;   Drug: Parenteral /oral Methadone ratio 1:1.2
Outcome Measures: Proportion of intoxicated patients in each groups;   Parenteral/oral MTD final ratio in patients considered as "failure"
19 Recruiting Methadone in Pediatric and Adult Sickle Cell Patients
Condition: Sickle Cell Disease
Interventions: Drug: Morphine;   Drug: Methadone
Outcome Measures: To determine the pharmacokinetics of Methadone in children and adults with Sickle Cell disease experiencing a VOE.;   Pain
20 Unknown  Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain
Conditions: Cancer;   Pain;   Palliative Care
Intervention: Drug: Methadone plus Acetaminophen or Placebo
Outcome Measures: Pain intensity and time to equianalgesic effect;   Degree of nausea, vomiting, obstipation, xerostomia and drowsiness